Abstract: Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic thioether.

Abstract: The present invention provides for methods and compounds for treating brain trauma and disorders such as: ischemia, stroke, neurodegenerative disorders, opioid addiction, idiopathic pain, epilepsy, and depression. More specifically, the invention provides methods for designing and identifying inhibitors of mammalian agmatinase and for compounds identified by these methods.

Abstract: The invention provides a novel class of xanthene dyes, some of which are functionalized to allow their coupling to conjugation partners of interest, e.g. biomolecules, drugs, toxins and the like. Also provided are conjugates of the dyes, methods of preparing and using the dyes and their conjugates and kits including the dyes and their conjugates.

Abstract: Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new-subclass of radiolabeled compounds, which are selective androgen receptor modulators (SARM), which demonstrate antiandrogenic activity of a nonsteroidal ligand for the androgen receptor, and/or which bind irreversibly to the androgen receptor. The present invention further provides methods for a) imaging of cancer in a subject, b) imaging an androgen receptor-containing tissue in a subject, c) in-vivo imaging in a subject, d) treating a subject suffering from prostate cancer, e) delaying the progression of prostate cancer in a subject suffering from prostate cancer, f) preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, and g) treating the recurrence of prostate cancer in a subject suffering from prostate cancer, which comprise using the radiolabeled compounds of the present invention.

Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10?3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s as contrast media in MR imaging for visualization of intravascular thrombi.

Abstract: A two-stage method of preparing essentially pure amino acid chelates, wherein the first stage comprises contacting a metal ion from a metal oxide or hydroxide with an amino acid thereby producing a metal hydroxyl amino acetate. The second stage comprises contacting the metal hydroxyl amino acetate from the first stage, with at least one amino-containing compound provided in excess thereby producing a reaction solution containing an amino acid chelate reaction product comprising a metal ion bound to a plurality of amino acid ligands wherein the plurality of amino acid ligands is equal to the coordination number of the metal ion, and then separating the amino acid chelate from the reaction solution. The second stage may include a plurality of steps for sequentially reacting the reaction product with a plurality of amino-containing compounds. The amino acid chelates thus produced can be incorporated into compositions comprising beverages, foodstuffs, nutraceuticals and pharmaceutical adjuvants.

Abstract: A new use in magnetic resonance imaging employing a field greater than 1.5 Tesla, of a porphyrin compound of the following general formula I is provided: in which R0 and R?0 are such that the compound is soluble in a biological medium, and M denotes a paramagnetic metal ion, advantageously Mn3+. The present invention also relates to novel porphyrin compounds.

Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.

Abstract: This invention provides novel cyclooxygenase-2 selective agents that are particularly useful as imaging probes in non-invasive imaging techniques, such as PET and SPECT. Preferred cyclooxygenase-2 selective agents inhibit cyclooxygenase-2 activity with greater potency and specificity than conventional cyclooxygenase-2 inhibitors. Other aspects of the invention include pharmaceutical compositions including the cyclooxygenase-2 selective agents as well as methods for detecting and/or inhibiting cyclooxygenase-2. These methods are particularly useful for diagnosing and treating disorders, such as inflammation, which is characterized by elevated cyclooxygenase-2 levels.

Abstract: Radioisotope generators comprising inorganic layered hydroxide composition, such as magnesium aluminates and lithium aluminates. These inorganic layered hydroxides form anion exchange materials that exhibit surprisingly high selective affinities for certain radioisotopes. Inorganic layered hydroxides have been prepared and shown to have high affinity for tungstate anions, the anion form of tungsten-188, yet low affinity for perrhenate anions, the anion form of rhenium-188.

Abstract: The invention includes methods and compounds for labelling conjugates with metals which comprise the steps of coupling the conjugate to a support surface; introducing a complex-forming metal to the support; and collecting the metal-conjugate complex released from the support. The metal catalyzes cleavage of the conjugate from the support upon complex formation resulting in a solutions substantially free of unlabeled conjugate.

Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

Abstract: The present invention relates to methods and compositions for wound healing, and in particular, methods and compositions to promote and enhance wound healing. In particular, the present invention provides MMP derived peptides for use in enhancing wound healing.

Abstract: The invention relates to a physiologically acceptable composition, in particular a cosmetic composition, containing at least one liquid fatty phase comprising at least one structuring polymer comprising a polymer skeleton having hydrocarbon-based repeating units containing at least one hetero atom, and and at least one gelling agent for the said fatty phase, the liquid fatty phase, the structuring polymer and the gelling agent forming a physiologically acceptable medium. This composition may be in the form of a stick of lipstick which is stable, which does not exude and whose application produces a glossy deposit with good staying power over time.

Abstract: A method for preparing a crystal of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid having a single endothermic peak approximately at 233° C. in differential scanning calorimetry, which comprises the step of recrystallizing a crystal of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid from a mixture of water and ethanol. The method enables selective preparation of type-II crystals which are stable against physical impact. The resulting crystals are free from highly toxic hexane as a residual solvent, and preferably used as an active ingredient of pharmaceuticals.

Abstract: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.

Abstract: Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

Abstract: Methods are provided for producing flowable compositions, e.g. pastes, that set into calcium phosphate products and include a contrast agent. In the subject methods, dry reactants that include a calcium source and a phosphate source are combined with setting fluid and a water-soluble contrast agent, e.g., a water-soluble barium salt, and the combined reactants are mixed to produce the flowable composition. Also provided are the compositions themselves as well as kits for preparing the same. The subject methods and compositions produced thereby find use in a variety of applications, including the repair of hard tissue defects, e.g., bone defects.

Abstract: A multifunctional cross-bridged tetraaza macrocyclic compound has at least one side arm that comprises a moiety that is capable of forming a bond with another molecule, which has a targeting moiety that directs the compound to a site a marker substance. The compound is chelated to a medically active material that generates a signal for diagnostic imaging or produces a therapeutic effect at the site of the marker substance. A method for detecting, diagnosing, and/or treating a disease that produces the marker substance uses a conjugate comprising the multifunctional cross-bridged tetraaza macrocyclic compound.

Abstract: Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.